| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 493.0 | 354.3 |
| Profit before tax | 290.6 | 219.0 |
| Net income | 247.0 | 175.2 |
| EPS (diluted, $ a share) | $2.01 | $1.43 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Net income, year on year | +41.0% |
|---|---|
| Revenue, year on year | +39.2% |
| Operating margin | 59.8% |
10-Q filed with the SEC, NASDAQ: HALO. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Halozyme Therapeutics, Inc.: key numbers
- Share price
- $95.97Close, Nov 17
- Market cap
- $10.9B
- Shares outstanding
- 114.01MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Biological Products, (No Diagnostic Substances)SIC 2836
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Halozyme Therapeutics, Inc.
All →Halozyme Therapeutics President and CEO Helen Torley Sells $6M of Stock
Helen Torley, President and CEO, sold 60,000 shares of Halozyme Therapeutics, Inc. at $96.85 to $101.72 a share (average $100.01) in 10 transactions, worth $6M in total between Nov 12, 2026 and Nov 16, 2026. Shares held after the trade: 767,780 (-0.0%).
- Value
- $6M
- Shares
- 60,000
- Average price
- $100.01
- Role
- President and CEO
- Holding change
- -0.0%
- Trade date
- Nov 12, 2026 to Nov 16, 2026
Halozyme Therapeutics Financial Results
Halozyme Therapeutics reported record Q3 2026 financial results with total revenue increasing 39% year-over-year to $493 million, driven by a 44% surge in royalty revenue. Based on strong performance, the company raised its full-year 2026 guidance for revenue, adjusted EBITDA, and non-GAAP EPS while highlighting a legal victory in the Netherlands protecting its intellectual property against Merck.
- Term
- Q3 2026
“Halozyme delivered another exceptional quarter, with total revenue increasing 39% and royalty revenue growing 44% year-over-year to record levels.”
Dr. Helen Torley, President and Chief Executive Officer
“Based on our strong financial performance this quarter, we are pleased to be able to raise our guidance for the full year 2026.”
Darren Snellgrove, Executive Vice President and Chief Financial Officer
Halozyme Therapeutics President and CEO Helen Torley Sells $6.61M of Stock
Helen Torley, President and CEO, sold 60,000 shares of Halozyme Therapeutics, Inc. at $107.90 to $113.69 a share (average $110.18) in 12 transactions, worth $6.61M in total between Oct 6, 2026 and Oct 8, 2026. Shares held after the trade: 767,780 (-0.0%).
- Value
- $6.61M
- Shares
- 60,000
- Average price
- $110.18
- Role
- President and CEO
- Holding change
- -0.0%
- Trade date
- Oct 6, 2026 to Oct 8, 2026
Halozyme Therapeutics Insider Matthew L. Posard Sells $568K of Stock
Matthew L. Posard sold 5,230 shares of Halozyme Therapeutics, Inc. at $107.17 to $110.04 a share (average $108.54) in 4 transactions, worth $568K in total on Oct 1, 2026. Shares held after the trade: 53,609 (-0.2%).
- Value
- $568K
- Shares
- 5,230
- Average price
- $108.54
- Holding change
- -0.2%
- Trade date
- Oct 1, 2026
Halozyme Therapeutics Leadership Change
Halozyme Therapeutics appointed James Daly to its Board of Directors, effective September 28, 2026. Mr. Daly will serve in the class of directors with a term ending at the 2029 annual meeting and will receive standard compensation under the company's non-employee director program.
- Counterparty
- James Daly
Halozyme Therapeutics $1.5B Debt Financing with The Bank of New York Mellon Trust Company, N.A.
Halozyme Therapeutics completed the sale of $1.5 billion in 1.50% Convertible Senior Notes due 2033, which included a $200 million overallotment option exercised by initial purchasers. The company used the proceeds to fund capped call transactions and to repurchase approximately $652.5 million of its existing 0.25% notes due 2027 and 1.00% notes due 2028.
- Value
- $1.5B
- Counterparty
- The Bank of New York Mellon Trust Company, N.A.
- Term
- through 2033